metaclazepam has been researched along with diazepam in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Blaschke, D; Hippius, H; Laakmann, G; Schewe, S | 1 |
| Laakmann, G; Schmauss, M; Schmitt, E; Treusch, J; Treusch, U | 1 |
2 trial(s) available for metaclazepam and diazepam
| Article | Year |
|---|---|
Double-blind study of metaclazepam versus diazepam treatment of outpatients with anxiety syndrome.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anxiety; Benzodiazepines; Blood Pressure; Clinical Trials as Topic; Diazepam; Double-Blind Method; Female; Heart Rate; Humans; Male; Middle Aged; Outpatients; Psychiatric Status Rating Scales; Random Allocation | 1989 |
Comparison of growth hormone stimulation induced by desimipramine, diazepam and metaclazepam in man.
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Desipramine; Diazepam; Dose-Response Relationship, Drug; Growth Hormone; Humans; Male; Time Factors | 1982 |
1 other study(ies) available for metaclazepam and diazepam
| Article | Year |
|---|---|
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |